Company / Shareholders' Equity
Arbutus Biopharma Corp Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$76.6M
FY2025
5-year range
$76.6M / $169.4M
FY2021-FY2025
Trend
-21.4%
vs FY2024
Sector context
#176 of 213
Health Care
What the data says
Arbutus Biopharma Corp's shareholders' equity of $77M is lower than 83% of companies in the Health Care sector (FY2025). Shareholders' Equity has declined for 4 consecutive years, from $169M in FY2021 to $77M in FY2025.
Based on SEC 10-K filings.
$77M in FY2025 with a 5-year CAGR of +1.0%.
Declined from $106M to $77M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -17.6%
- 5-Year CAGR
- +1.0%
- 10-Year CAGR
- -
Sector benchmark
Bottom 17% in Health CareTop 83% of 213This company $76.6M Sector average $2.5B
▼
-97.0% below sector average
Key checks
Key Insights
- Arbutus Biopharma Corp's shareholders' equity has declined for 4 consecutive years.
- 5-year CAGR of +1.0%, indicating consistent growth.
- In FY2025, shareholders' equity decreased 21.4% year-over-year.
- Ranks #176 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -11.01 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $76.6M | -21.4% |
| FY2024 | $97.4M | -8.2% |
| FY2023 | $106.0M | -22.5% |
| FY2022 | $136.9M | -19.2% |
| FY2021 | $169.4M | +132.9% |
| FY2020 | $72.7M | -63.7% |
| FY2019 | $200.2M | +9.7% |
| FY2018 | $182.5M | +0.0% |
| FY2017 | $182.5M | -10.1% |
| FY2016 | $203.0M | -62.9% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026